By David Cassak
Things like this weren't supposed to happen.
Guidant's Loss of Innocence
Since its 1994 spin off, Guidant has built itself into one of the leading cardiovascular device companies through a deft technology innovation. But a series of recent missteps, most visibly in its AAA graft business but most importantly in its drug-eluting stent business, has caused this former start-up to grow up quickly. But Guidant officials counter that the AAA problems will quickly be put behind and that the drug-eluting stent program will emerge a winner, every bit as strong as its traditional bare metal stent business and its currently robust cardiac rhythm management business.
More from Leadership
More from In Vivo
• By
Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.
• By
From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.
• By
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.